82 selected records with a cited source date in 2012. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT00811395 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-12-31, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00097747 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00228436 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00228449 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00272662 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.
The official Drugs@FDA dataset lists original submission 1 for NDA 203441 with status AP dated 2012-12-21, and names teduglutide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00252187 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-12-20, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00295750 at 2026-11-15T21:52:09.579Z. Its registry update date was 2012-12-19, and PeptideScanner's reviewed identity mapping was degarelix.
The Federal Register published notice 2012-30308, attributed to FDA and its parent HHS department, on 2012-12-17. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
The official Drugs@FDA dataset lists original submission 1 for NDA 200677 with status AP dated 2012-12-14, and names pasireotide diaspartate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00426751 at 2026-11-15T21:59:29.646Z. Its registry update date was 2012-11-27, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT00426153 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-11-21, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01446783 at 2026-11-16T17:35:13.282Z. Its registry update date was 2012-11-20, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT00906347 at 2026-11-16T00:59:19.138Z. Its registry update date was 2012-11-15, and PeptideScanner's reviewed identity mapping was oxytocin.
PubMed lists PMID 10512687 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 10611139 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 19198769 in Advances in therapy as Journal Article, Review, with publication-date metadata of 2009-01-28 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 19228148 in BJU international as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 9534309 in Cardiologia (Rome, Italy) as Journal Article, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 9589671 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 9694949 in The Journal of pharmacology and experimental therapeutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 10373343 at 2026-07-30T22:15:26.481Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 1999-06-22. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 12195242 at 2026-07-30T22:15:26.486Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2002-08-27. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 12500162 at 2026-07-30T22:15:26.487Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2002-12-25. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 12500171 at 2026-07-30T22:15:26.487Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2002-12-25. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 16634527 at 2026-07-30T22:15:26.490Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2006-04-26. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00475865 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-11-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
The Federal Register published rule 2012-25989, attributed to FDA and its parent HHS department, on 2012-10-23. Its official title is “New Animal Drugs; Approvals; Changes of Sponsor; Change of Sponsor's Name; Change of Sponsor's Address; Alfaxalone; Ivermectin and Clorsulon; Narasin; Triptorelin,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin.
The Federal Register published notice 2012-25483, attributed to FDA and its parent HHS department, on 2012-10-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT01695109 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-09-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained PubMed bibliographic metadata for PMID 22986396 at 2026-07-30T22:15:26.556Z. PubMed recorded a metadata revision date of 2012-09-18 and an Entrez history date of 2012-09-19. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.
The Federal Register published notice 2012-22658, attributed to FDA and its parent HHS department, on 2012-09-14. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.
DailyMed lists Structured Product Labeling version 2 for the reviewed Linaclotide label family with a published date of 2012-09-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2012-22195, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
The Federal Register published rule 2012-22196, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “New Animal Drugs; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT00605267 at 2026-11-15T21:50:32.222Z. Its registry update date was 2012-09-06, and PeptideScanner's reviewed identity mapping was goserelin.
The official Drugs@FDA dataset lists original submission 1 for NDA 202811 with status AP dated 2012-08-30, and names linaclotide among the application record's active ingredients.
PeptideScanner retained PubMed bibliographic metadata for PMID 22753275 at 2026-07-30T22:15:26.545Z. PubMed recorded a metadata revision date of 2012-08-23 and an Entrez history date of 2012-07-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
The Federal Register published notice 2012-20612, attributed to FDA and its parent HHS department, on 2012-08-22. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00752791 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-08-15, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00667758 at 2026-11-15T22:02:39.332Z. Its registry update date was 2012-08-06, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT00752609 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-07-27, and PeptideScanner's reviewed identity mapping was peginesatide.
The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01184872 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-07-13, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01637454 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-07-11, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00003026 at 2026-11-15T21:49:16.513Z. Its registry update date was 2012-07-02, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00434330 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00680043 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT01078805 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-26, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00666224 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-06-25, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01056549 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-22, and PeptideScanner's reviewed identity mapping was exenatide.
PubMed lists PMID 22702061 in Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery as English Abstract, Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-05 (month precision). PeptideScanner associated the retained record with the identity slug peg-mgf. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00004895 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-06, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00334022 at 2026-11-16T01:41:15.051Z. Its registry update date was 2012-06-05, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT01184859 at 2026-11-16T01:33:21.554Z. Its registry update date was 2012-05-25, and PeptideScanner's reviewed identity mapping was desmopressin.
The Federal Register published notice 2012-12040, attributed to FDA and its parent HHS department, on 2012-05-18. Its official title is “Determination That PITRESSIN TANNATE IN OIL (Vasopressin Tannate) Injection, 5 Pressor Units/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00387621 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-05-17, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00373451 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-05-08, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT01028768 at 2026-11-15T21:55:23.600Z. Its registry update date was 2012-05-07, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01028924 at 2026-11-15T21:55:23.600Z. Its registry update date was 2012-05-07, and PeptideScanner's reviewed identity mapping was teduglutide.
The Federal Register published notice 2012-10808, attributed to FDA and its parent HHS department, on 2012-05-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.
The Federal Register published notice 2012-10517, attributed to FDA and its parent HHS department, on 2012-05-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01588093 at 2026-11-16T17:35:13.282Z. Its registry update date was 2012-04-30, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT00171613 at 2026-07-30T22:14:20.909Z. Its registry update date was 2012-04-30, and PeptideScanner's reviewed identity mapping was octreotide.
The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01580514 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-04-19, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01080963 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-04-17, and PeptideScanner's reviewed identity mapping was daptomycin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 077212 with status AP dated 2012-04-12, and names desmopressin acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01031966 at 2026-11-15T22:10:40.222Z. Its registry update date was 2012-03-29, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients.
The Federal Register published notice 2012-6971, attributed to FDA and its parent HHS department, on 2012-03-23. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Secretin.
PeptideScanner retained ClinicalTrials.gov record NCT00653757 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-03-19, and PeptideScanner's reviewed identity mapping was leuprolide.
The Federal Register published notice 2012-4037, attributed to FDA and its parent HHS department, on 2012-02-22. Its official title is “Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01373606 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00257426 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained PubMed bibliographic metadata for PMID 20610447 at 2026-07-30T22:15:26.499Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-07-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 20436114 at 2026-07-30T22:15:26.497Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-05-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
PubMed lists PMID 22098485 in FEMS microbiology letters as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2011-12-08 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for NDA 022200 with status AP dated 2012-01-27, and names exenatide synthetic among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00805935 at 2026-07-30T22:14:20.915Z. Its registry update date was 2012-01-27, and PeptideScanner's reviewed identity mapping was leuprolide.
The Federal Register published notice 2012-1433, attributed to FDA and its parent HHS department, on 2012-01-25. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00079586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-01-05, and PeptideScanner's reviewed identity mapping was bivalirudin.